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Cognitive impairment, including dementia, is a common but
poorly recognized problem among patients with end-stage
renal disease (ESRD), affecting 16–38% of patients. Dementia
is associated with high risks of death, dialysis withdrawal,
hospitalization, and disability among patients with ESRD;
thus, recognizing and effectively managing cognitive
impairment may improve clinical care. Dementia screening
strategies should take into account patient factors, the time
available, the timing of assessments relative to dialysis
treatments, and the implications of a positive screen for
subsequent management (for example, transplantation).
Additional diagnostic testing in patients with cognitive
impairment, including neuroimaging, is largely based on the
clinical evaluation. There is limited data on the efficacy and
safety of pharmacotherapy for dementia in the setting of
ESRD; therefore, decisions about the use of these
medications should be individualized. Management of
behavioral symptoms, evaluation of patient safety, and
advance care planning are important components of
dementia management. Prevention strategies targeting
vascular risk factor modification, and physical and cognitive
activity have shown promise in the general population and
may be reasonably extrapolated to the ESRD population.
Modification of ESRD-associated factors such as anemia
and dialysis dose or frequency require further study before
they can be recommended for treatment or prevention of
cognitive impairment.
Kidney International (2011) 79, 14–22; doi:10.1038/ki.2010.336;
published online 22 September 2010
KEYWORDS: aging; cognitive impairment; dementia; ESRD
Cognitive disorders have long been recognized as a
complication of end-stage renal disease (ESRD) and its
treatment; yet guidelines for the detection, prevention, and
management of these disorders are lacking. Evidence is
mounting that cognitive impairment is common among
‘adequately’ dialyzed patients, and that it may in turn affect
ESRD management and outcomes in several adverse ways.
This review outlines the rationale and tools for assessment of
cognitive function and provides recommendations for the
management of cognitive impairment and dementia among
adults with ESRD.
DEFINITION OF TERMS
Dementia is a state of persistent and progressive cognitive
dysfunction characterized by impairment in memory and at
least one other aspect, or domain, of cognitive function, such
as language, orientation, reasoning, attention, or executive
functioning, the cognitive skill necessary for planning and
sequencing tasks.1 The impairment in cognitive function
must represent a decline from the patient’s baseline level of
cognitive function and must be severe enough to interfere
with daily activities and independence. Alzheimer’s disease is
the most common form of dementia in the general
population, whereas vascular dementia, either alone or in
combination with Alzheimer’s disease, is the second most
common form of dementia in the United States.2 Dementia
associated with Parkinson’s disease and other dementia
syndromes account for the remaining 10–20% of dementia
cases. Dialysis dementia is a term used to describe a rapidly
progressive form of dementia, now considered rare, asso-
ciated with aluminum toxicity in ESRD patients.3
Mild cognitive impairment is the most common terminol-
ogy used to describe cognitive impairment beyond that
associated with normal aging, but not crossing the threshold
for dementia. Among elderly patients with mild cognitive
impairment in the general population (as variously defined),
the annual conversion rate to dementia ranges from 5 to
20%;4,5 therefore, these patients merit close follow-up.
Delirium is a syndrome of cognitive impairment
characterized by inattention and altered consciousness
attributable to a medical condition, medication side effect,
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or intoxication.1 In contrast to dementia, delirium develops
over a short period of time and its course is often fluctuating
(Table 1). Delirium and dementia often coexist, although the
nature of their relationship is complex, and this may
contribute to difficulty in distinguishing between these
disorders. The classic descriptions of uremic encephalopathy
and dialysis disequilibrium are of delirium syndromes
attributed to retention of as yet unidentified uremic solutes
and brain edema during dialysis, respectively.6,7 Earlier
initiation of dialysis and the use of preventative measures
for dialysis disequilibrium seem to have reduced the
incidence of these syndromes, or at least their most severe
presentations. In small studies, temporal fluctuations in
cognitive function have been identified among hemodialysis
patients, suggesting that subacute forms of these syndromes
may exist.8,9 Whether patients with these temporal fluctua-
tions in cognition are at higher risk for chronic or progressive
cognitive impairment is not clear. Nevertheless, the develop-
ment of delirium, regardless of its cause, in a patient with
ESRD should heighten suspicion for underlying dementia.
IMPORTANCE OF ASSESSING COGNITIVE FUNCTION
IN PATIENTS WITH ESRD
Dementia is common but poorly recognized
The prevalence of cognitive impairment, as assessed using
neuropsychological tests among patients with ESRD, ranges
from 16 to 38% depending on the sample and the definition
of impairment.10–16 These rates are approximately threefold
higher than the age-matched general population and
substantially higher than the reported prevalence rate of
dementia based on Medicare claims data,17 suggesting that
nephrologists, similar to primary care physicians, are poor at
recognizing and documenting dementia. For example, in two
studies, o15% of ESRD patients with cognitive impairment
had chart documentation.11,12 Further, subjective complaints
of confusion and ESRD clinical performance measures are
not highly correlated with the presence of cognitive
impairment in ESRD patients.16,18 Thus, periodic screening
is needed to accurately identify patients with cognitive
impairment in order to improve their clinical care.
Cognitive impairment complicates ESRD management and
contributes to poor outcomes
Why should busy nephrologists spend time assessing
cognitive function, especially when the available treatments
for dementia and more mild cognitive impairment have
modest efficacy, at best? First, if cognitive impairment is not
recognized, then potentially reversible causes of impairment,
such as delirium or depression, cannot be identified and
treated. Second, cognitive impairment may interfere with
capacity for self-care and informed decision-making. For
example, cognitive impairment may hinder adherence with
the complex regimens often prescribed to patients with
ESRD, increase the risk of adverse drug events, and impair
informed decision-making surrounding issues such as
preemptive vascular access placement and ESRD treatment
options.19–21 Indeed, the high burden of cognitive impair-
ment may explain, in part, why ESRD clinical performance
targets have been so difficult to achieve. Third, dementia
increases the risk for poor outcomes, including disability,
hospitalization, withdrawal from dialysis, and death,17,22–25
and increases the cost of care. The clinical significance of
cognitive impairment not meeting criteria for dementia has
not been fully elucidated, although some evidence suggests
that it may also be associated with poor outcomes.12 Fourth,
a definitive diagnosis of dementia may provide an opportu-
nity to define goals of care and facilitate end-of-life care
planning before the disease becomes advanced. Fifth,
although the available pharmacological therapy for dementia
may have modest efficacy, newer treatments currently under
development may prove even more successful in slowing
disease progression. Thus, identifying dementia or severe
cognitive impairment may lead to the institution of
supportive care measures that improve outcomes and reduce
disease burden.
WHO IS AT RISK FOR COGNITIVE IMPAIRMENT AND
DEMENTIA?
Similar to the general population, a dementia diagnosis is
more common among the elderly, women, and non-white
patients with ESRD, and less common among patients
receiving peritoneal dialysis and transplant recipients,
possibly reflecting patient selection and ascertainment
bias.23,25 Advanced age is a major risk factor for dementia
and cognitive impairment—30–55% of ESRD patients over
the age of 75 years have cognitive impairment based on
neuropsychological testing (Figure 1).11,15 Recognition of the
burden of impairment in this age group is essential for
effective management of ESRD comorbidities. The prevalence
of cognitive impairment ranges from 10 to 30% among
Table 1 | Differentiating features of dementia, delirium, and depression
Feature Dementia Delirium Depression
Onset Insidious Acute Acute or insidious
Course Progressive Fluctuating Stable or fluctuating
Duration Months to years Days to months Months to years
Consciousness Intact except in advanced dementia Altered Intact
Complaints of memory loss Variable Absent Usually present
Psychomotor change Usually normal until advanced Increased or decreased Normal or decreased
Reversibility Rarely Usually Usually
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young or middle-aged patients with ESRD (Figure 1);
therefore, screening strategies based only on age may
miss a significant fraction of ESRD patients with clinically
important cognitive impairment. Cognitive decline
begins well before the development of ESRD, such that
prevalence rates of dementia and cognitive impairment
among older individuals with advanced chronic kidney
disease (CKD) approximate those seen in patients with
ESRD (Figure 2).26–30
The neuropathology of cognitive impairment and demen-
tia in ESRD is unknown, although several lines of evidence
indicate that cerebrovascular disease may have a prominent
role. The vascular beds of the brain and kidney have similar
anatomic and hemodynamic features; these observations
have led to the speculation that cognitive impairment and
CKD (including microalbuminuria) are reflections of vas-
cular injury in different end organs (Figure 3). Brain
magnetic resonance imaging among unselected patients with
CKD and ESRD demonstrates a large burden of large vessel
stroke, small vessel stroke (lacunes), and white matter lesions
(resulting from small vessel ischemia).31–35 In prospective
studies, CKD independently predicts stroke and cognitive
decline,26 and cerebral small vessel disease independently
predicts risk for ESRD among patients with diabetes,36
suggesting that CKD and cognitive impairment share a
common pathogenesis. Among patients with CKD and
ESRD, stroke is a major risk factor for cognitive decline
and dementia, and in contrast to the general population, the
incidence of vascular dementia may approach or exceed the
incidence of Alzheimer’s disease.27,37
Yet, this may be an oversimplification, as there is
considerable overlap in risk factors, clinical features, and
radiographic and neuropathological findings between Alz-
heimer’s disease and vascular dementia, and it is now
recognized that vascular lesions may modify the course of
Alzheimer’s disease and that Alzheimer’s disease may modify
the course of vascular dementia.38 Indeed, cerebrovascular
disease lesions identified by structural magnetic resonance
imaging are not consistently correlated with cognitive
function in patients with ESRD.39–41 Furthermore, in several
studies, CKD is associated with cognitive decline and
dementia, independent of traditional vascular risk factors
such as hypertension and diabetes, suggesting that factors
associated with CKD and its treatment may be implicated in
the pathogenesis of cognitive impairment.26–28 Nontradi-
tional or ‘nephrogenic’ risk factors such as anemia and
albuminuria are associated with cognitive impairment and
dementia in several studies.11,42–44 The role of other
nephrogenic factors such as retention of uremic solutes,
inflammation, oxidative stress, and vascular calcification;
treatment-related factors such as intradialytic hypotension
and hyperviscosity; and genetic factors such as apolipopro-
tein E or cystatin-c status has not been adequately studied in
the ESRD population (Figure 3), but many of these factors
have been associated with cognitive impairment among
elderly without kidney disease.45–48
SCREENING FOR COGNITIVE IMPAIRMENT
The optimal timing, frequency, and instruments for
assessment of cognitive function in ESRD patients will
depend on the clinical setting. For example, assessment of
cognitive function during a hemodialysis session may be
useful when trying to determine whether information
communicated during rounds is understood, but in most
other circumstances, assessment before or the day
after dialysis would be preferred. Given the high prevalence
of impairment among patients with CKD and the implica-
tions of a diagnosis of dementia on decision-making,
screening for cognitive impairment should start before the
onset of ESRD.
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Figure 1 |Prevalence of cognitive impairment among patients
with end-stage renal disease (ESRD) by age group. Note: The
clinical trial sample consisted of 383 hemodialysis patients
participating in the Frequent Hemodialysis Network Trials.
Cognitive impairment was defined as a Modified Mini-Mental
State Exam score o80 (ref. 15). The community sample consisted
of 374 hemodialysis patients in Minnesota. Cognitive impairment
was defined according to performance on a neuropsychological
battery.11
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Figure 2 |Prevalence of cognitive impairment among 23 405
US adults, according to estimated glomerular filtration rate
(GFR). Data are adapted from Kurella Tamura et al.30
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A large number of screening tests are available with a
range of administration times and diagnostic accuracy.49–52
Table 2 lists the performance characteristics of several
commonly used cognitive screening instruments that can
be administered in p10 min. Scores on many screening
instruments are influenced by age, educational level, and
English fluency. Several tests also have ‘ceiling effects’,
resulting in lower sensitivity for detecting dementia among
highly educated patients and for detecting mild cognitive
impairment. To our knowledge, no studies have validated the
various cognitive screening instruments against a clinical
diagnosis of dementia among patients with ESRD.
The Mini-Mental State Exam (MMSE) is perhaps the
best known and most studied cognitive test for dementia
screening.52 A score ofo24 (out of a maximum score of 30)
has 480% sensitivity and specificity for dementia detection
in several studies in the general population.49,53 Normative
scores for age and educational level have been published.54
The MMSE also has several drawbacks, including copyright
protection and the lack of executive function assessment. As
deficits in executive function are a prominent feature of
dementia from vascular causes and appear to be common
among patients with ESRD,15,55 this may limit its sensitivity
for dementia detection in the ESRD population. Newer
instruments have been developed (for example, the Modified
MMSE (3MS), St Louis University Mental Test (SLUMS),
Montreal Cognitive Assessment (MoCA)) that address some
of the limitations of the MMSE (Table 2).
Other screening tests that can be administered inp5 min,
such as the Six-item Screener, the clock drawing task, and the
Mini-cog (clock drawing plus uncued recall of three words)
are reasonable options when time is limited. The Kidney
Disease Quality of Life (KDQOL) cognitive function subscale
has the advantage of using self-report and has been validated
against the 3MS,18 but its sensitivity is lower than other
brief screening instruments. One suggested screening strategy
might be annual screening using a brief tool (for example
Mini-cog), beginning before the onset of ESRD to establish
the patient’s baseline level of functioning and to evaluate
whether cognitive impairment might be complicating CKD
management. A longer assessment tool (for example, MMSE,
MoCA) might be used in highly educated patients or when
greater specificity is needed and more time is available.
Although these tests (with the exception of the KDQOL)
generally have high sensitivity, specificity varies. Therefore,
referral for neuropsychological testing should be considered
for more extensive evaluation in complicated cases, such as
determining the capacity for decision-making and establish-
ing the diagnosis in patients with limited English proficiency
or transplant candidates. These evaluations, typically lasting
several hours, assess a range of cognitive domains more
thoroughly than do screening instruments. Neuropsycholo-
gical testing, when considered in conjunction with the history
and physical examination, can confirm the diagnosis of
dementia and provide clues to the underlying etiology, as
different causes of dementia may feature deficits in one
cognitive domain more prominently. In our opinion,
neuropsychological testing is also valuable before initiation
of pharmacotherapy to document the severity of dementia
and follow the response to treatment.
Shared risk factors
Age
Non-white race
Low socioeconomic status/
low education
Diabetes
Hypertension
Hyperlipidemia
Others
Nephrogenic risk factors
Albuminuria
Anemia
Retention of uremic solutes
Inflammation
Oxidative stress
Vascular calcification
Hyponatremia
Others
ESRD treatment-associated risk factors
Intradialytic hypotension
Cerebral edema (dialysis dysequilibrium)
Hyperviscosity and thrombotic events
Others
Neurodegenerative
disease
Microvascular
disease
Direct neuronal
injury
Hypoperfusion
Dementia
Figure 3 |Proposed mechanisms of dementia in end-stage renal disease (ESRD).
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EVALUATION OF COGNITIVE IMPAIRMENT
History taking, ideally from the patient and caregiver, should
focus on the onset, duration, and severity of cognitive and
behavioral deficits, the presence of associated functional
impairments (for example, difficulty in handling finances),
and symptoms of depression or sleep disturbance. Caregivers
often notice cognitive deficits before they are apparent to
clinicians, and their observations or the availability of a pre-
ESRD cognitive assessment is useful for helping to establish
the course of impairment and for differentiating delirium
from dementia. The examiner should look for focal neuro-
logical deficits suggestive of previous stroke and signs of
Parkinsonism (for example, tremor, bradykinesia, or rigidity).
It is important to try to exclude delirium or depression as
the sole cause of cognitive impairment before establishing a
diagnosis of dementia, as these conditions are reversible,
although, in practice, this may be difficult. Common causes
of delirium include electrolyte disturbances (for example,
hypoglycemia, hyponatremia, and hypercalcemia), medica-
tion side effects (opioids, benzodiazepines, antihistamines,
antipsychotics, and anticholinergics), infections (catheter-
related bacteremia or central nervous system infection),
hypertensive encephalopathy, intoxications, alcohol with-
drawal, and other organ failure states (cardiac or liver
disease). Patients with symptoms of sleep disorders should be
referred for confirmatory testing and treated, if indicated.
Unnecessary or ineffective medications with central nervous
system activity should be discontinued.15 Laboratory testing
for B12 deficiency and hypothyroidism is recommended for
all patients with suspected dementia. In ESRD patients,
inadequate dialysis, severe anemia, and aluminum toxicity
should also be ruled out. AIDS dementia complex should be
considered in patients with human immunodeficiency virus
risk factors. Testing for genetic markers of dementia risk (for
example, apolipoprotein E variants) remains primarily in the
research setting. Similarly, until the significance of neuroima-
ging abnormalities is more clearly defined, routine neuro-
imaging is probably not warranted but should be based on
results of clinical findings.
MANAGEMENT STRATEGIES
Two classes of medications are now available for treatment
of Alzheimer’s disease, cholinesterase inhibitors (tacrine,
donepezil, rivastigmine, and galantamine) and N-methyl
Table 2 | Performance characteristics of selected dementia screening instruments
Instrument
Administration
time (minutes)
Domains
evaluated Sensitivity Specificity
Positive
screen
cutpoint
Validation
reference
standard
Validated
in CKD or
ESRD Comments
Kidney disease
quality of life
(KDQOL) cognitive
function subscale
1–2 Self-report 52 82 60 Modified Mini-Mental
State Exam o80
Yes
Six-item screener 1–2 Orientation
Recall
90–97 69–79 X2 Errors Clinical assessment
for dementia
No
Clock drawing task 1–3 Visuospatial
Executive
function
85 85 Various Clinical assessment
for dementia
No Less cultural bias
Evaluates executive
function
Mini-cog 3–4 Visuospatial
Executive
function
Recall
76 89 2 Neuropsychological
battery
No Clock drawing task
plus uncued recall of
three words
Mini-Mental State
Exam (MMSE)
7–10 Orientation
Recall
Attention
Visuospatial
71–92 56–96 23–25 Clinical assessment
for dementia
No Norms available
Copyrighted
Does not assess
executive function
well
St Louis University
Mental Status Exam
(SLUMS)
7–10 Orientation
Recall
Attention
Visuospatial
Executive
function
98–100 91–100 21.5 Clinical assessment
for dementia
No Evaluates executive
function
Montreal Cognitive
Assessment (MoCA)
10 Orientation
Recall
Attention
Visuospatial
Verbal fluency
Executive
function
100 87 25 Neuropsychological
battery
No Evaluates executive
function
Abbreviations: CKD, chronic kidney disease, ESRD, end-stage renal disease.
Note: the sensitivity, specificity, and positive screen cutpoints listed above are for the general population (except for the KDQOL), as most of the above tests have not been
validated in patients with ESRD.
Adapted from Holsinger et al.,49 Tariq et al.,50 Nasreddine et al.,51 and Folstein et al.52
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D-aspartate receptor antagonists (memantine).56–60 Rivastig-
mine, galantamine, and memantine may also have efficacy in
patients with vascular dementia and/or dementia with mixed
features (that is, features of Alzheimer’s disease and vascular
dementia), but do not have food and drug administration
approval for this indication (Table 3).61 The clinical benefit of
both classes of agents appears to be modest (roughly
equivalent to a 4- to 6-month delay in cognitive decline),
and the effect of treatment on long-term outcomes remains
unclear. There is no published data on safety or efficacy of
these agents in ESRD patients; thus, therapy decisions should
be individualized.
Behavioral symptoms associated with dementia, such as
agitation or hallucinations are a prominent feature with more
severe impairment and are especially distressing to patients
and caregivers. These symptoms should be treated with a
stepped approach, beginning with removal of precipitating
factors (for example, pain and excessive noise), followed by
psychosocial interventions, and pharmacological therapy as a
last step, as many medications have not been shown to be
efficacious or have significant adverse events.62 For example,
several atypical antipsychotics have been associated with an
increased risk of stroke and death among elderly patients
with dementia.63 Caregivers should be encouraged to
accompany patients to their treatments, if possible, as this
may alleviate the patient’s anxiety and reduce the need for
pharmacological therapy. Key aspects of dementia manage-
ment are the assessment of patient safety and ability to
perform self-care functions, comply with medical regimens,
participate in medical decision-making, and plan for future
care needs. A multi-disciplinary approach involving primary
care, geriatrics, nursing, and social work is useful for
addressing the complexity of medical and social issues in
these patients.
The management of ESRD patients with mild cognitive
impairment is uncertain. There is conflicting evidence
regarding the role of vascular risk factor modification for
prevention of dementia in the general population. For
example, in a meta-analysis of hypertension trials, treatment
of hypertension was associated with a 13% risk reduction for
dementia.64 In contrast, a systematic review of hypertension
trials that excluded participants with preexisting cerebro-
vascular disease suggested no benefit of hypertension
treatment for preventing cognitive decline, but also no harm,
as had been suggested in a few smaller studies.65 Clinical
trials targeting glycemic and lipid control are in progress.
Homocysteine lowering with B vitamin supplementation has
failed to show benefit for reducing the risk of cognitive
decline, both in the general population and in the
CKD/ESRD population.13 Physical activity and cognitive
Table 3 | Pharmacological therapy for dementia
Drug class Indication
Route of
elimination
Usual starting
dose
Dose modification in
kidney disease?
Common side
effects
Cholinesterase inhibitors
Tacrine Mild-to-moderate
dementia from
Alzheimer’s disease
(used less commonly
because of dosing
frequency and need
for lab monitoring)
Extensive hepatic
metabolism
10mg every 6 h No data, but
probably not
required
Dizziness, nausea,
diarrhea, elevated
transaminases,
myalgia, neutropenia
Donepezil Mild-to-severe
dementia from
Alzheimer’s disease
Partially excreted in
unchanged form in
urine and partially
metabolized in liver
5mg at bedtime Very limited data
suggest that no dose
modification is
required
Dizziness, nausea,
diarrhea, myalgia,
insomnia
Rivastigmine Mild-to-moderate
dementia from
Alzheimer’s disease
Extensive hepatic
metabolism,
metabolites excreted
in urine
1.5mg twice a day Very limited data
suggest that no dose
modification is
required
Dizziness, nausea,
diarrhea, anorexia
Galantamine Mild-to-moderate
dementia from
Alzheimer’s disease
Partially excreted in
unchanged form in
urine and partially
metabolized in liver
4mg twice a day Maximum dose
16mg daily in
‘moderate’ kidney
disease. Use not
recommended in
ESRD
Dizziness, nausea,
diarrhea, anorexia
N-methyl D-aspartate receptor antagonists
Memantine Moderate-to-severe
dementia from
Alzheimer’s disease
Partially excreted in
unchanged form in
urine and partially
metabolized in liver
5mg daily Maximum dose 5mg
twice a day for
patients with
creatinine clearance
o30ml/min or ESRD
Dizziness,
hypertension,
headache,
constipation
Abbreviation: ESRD, end-stage renal disease.
Adapted from Memantine,56 Tacrine hydrochlorine,57 Donepezil hydrochloride,58 Rivastigmine tartrate,59 and Galantamine.60
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activity have shown promise as effective interventions to
slow cognitive decline in the general population.66 Given
the other benefits of physical activity, in particular, and
the relatively low risk of harm, these interventions may be
attractive options for patients with ESRD and deserve further
study.
Treatment of severe anemia with recombinant erythro-
poietin has been associated with improvement in neuropsy-
chological test performance and electroencephalography
measures in uncontrolled studies of patients with ESRD
conducted in the early 1990s.67,68 The lack of control arms in
these studies impairs the interpretation of these results, as
learning effects can influence cognitive performance. It
should be noted that pretreatment hematocrit in these
studies was substantially lower than current practice (mean
B23%), and that achieved posttreatment hematocrit was
consistent with current clinical practice guidelines (30–36%).
One study suggested that normalization of hematocrit with
erythropoietin was associated with further improvements in
cognitive function,69 and others have suggested that ery-
thropoietin may have neuroprotective effects independent of
raising hemoglobin concentration. Large randomized trials of
anemia correction using erythropoietin in CKD or ESRD did
not evaluate cognitive function, and one suggested that active
treatment was associated with an increased risk for stroke,70
which in turn is a major risk factor for dementia. Thus, there
is currently insufficient evidence to justify changing current
hemoglobin targets for the purposes of preventing dementia
in patients with CKD or ESRD.
Similarly, although it is accepted that dialysis initiation
reverses uremic encephalopathy, it is unknown whether even
higher dialysis dose may improve cognitive function. In two
observational studies of hemodialysis patients, higher Kt/V
was associated with poorer cognitive function.11,15 Whether
these findings were attributable to a deleterious effect of more
intensive thrice-weekly dialysis or to confounding by
indication and malnutrition is not clear. More frequent
hemodialysis may be a potential management strategy in
selected patients based on a small uncontrolled study of
patients converting from conventional thrice-weekly hemo-
dialysis to nocturnal hemodialysis;71 more definitive results
may soon be available from randomized clinical trials. In
short-term observational studies, kidney transplantation is
associated with improvement in cognitive function;72 how-
ever, other studies suggest that significant residual impair-
ment exists in some transplant recipients.73
ETHICAL AND HEALTH POLICY IMPLICATIONS
Guidelines from the Renal Physician’s Association suggest
that it is appropriate to forego or withdraw dialysis from a
patient with advanced dementia, especially if there are
behavioral symptoms that impede the safe provision of
dialysis.74 Surveys suggest that there is substantial practice
variation surrounding this issue,75 highlighting the impor-
tance of prognostic discussions before the disease becomes
advanced. These discussions are important for defining goals
of care, and also for helping patients and caregivers
understand what to expect, including anticipating the need
for an escalation in care needs. In cases in which it is not clear
whether a patient with severe cognitive impairment suffers
from uremic encephalopathy or dementia, a time-limited
trial of dialysis may be warranted. It is useful in these
circumstances to be as explicit as possible about expectations
beforehand, so that family members are not surprised about
the indications for withdrawal of dialysis. For example,
family members should be informed that it is not reasonable
to forcibly dialyze a severely demented patient who is
uncooperative with treatment. Hospice services are under-
utilized among ESRD patients, yet may reduce unnecessary
interventions and improve the quality of dying for ESRD
patients with advanced dementia.
Although conducting research in individuals with cogni-
tive impairment is crucial for improving care, it is also
important to protect vulnerable participants. ESRD research-
ers must be familiar with methods to assess decision-making
capacity and the use of surrogate decision makers to obtain
informed consent.21 Finally, proposed ESRD quality im-
provement measures, pay for performance schemes, and new
plans for reimbursement of ESRD services have generally
failed to acknowledge the extent to which factors such as
cognitive impairment might influence self-care and out-
comes, or the additional time and cost required to provide
optimal care for these patients.
SUMMARY
In summary, cognitive impairment including dementia is
common among patients with ESRD and likely to contribute
to adverse outcomes. Although available pharmacotherapy
for dementia may have a limited role in patients with ESRD,
other components of dementia care, such as management of
behavioral symptoms, assessment of patient safety, and
planning for future care needs, may reduce the burden of
the disease and improve quality of life. Modification of
vascular risk factors is a reasonable prevention strategy,
although not specifically tested in patients with ESRD, whereas
the role of interventions targeting proposed ESRD-associated
risk factors such as anemia and dialysis dose awaits clarification
from clinical trials. Given the aging of the ESRD population
and the burdens of cognitive impairment, additional investiga-
tions in this area are desperately needed to inform clinical
practice.
DISCLOSURE
MKT receives support from the National Institute of Aging
(K23AG028952) and from a Norman S. Coplon grant from Satellite
Research. She has previously received funding support from Amgen.
KY is supported by R01DK069406 from the National Institute of
Diabetes and Digestive and Kidney Diseases. She serves on a data
safety monitoring board for Pfizer and Medivation, and as a
consultant to Novartis.
ACKNOWLEDGMENTS
We thank Kirsten Johansen and Glenn Chertow for their thoughtful
review of earlier versions of the paper.
20 Kidney International (2011) 79, 14–22
min i rev iew M Kurella Tamura and K Yaffe: Dementia and cognitive impairment in ESRD
REFERENCES
1. American Psychiatric Association. Task Force on DSM-IV. Diagnostic and
Statistical Manual of Mental Disorders: DSM-IV, 4th edn. American
Psychiatric Association: Washington, DC, 1994: xxvii, 886pp.
2. Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med 2010; 362:
329–344.
3. Rozas VV, Port FK, Rutt WM. Progressive dialysis encephalopathy from
dialysate aluminum. Arch Intern Med 1978; 138: 1375–1377.
4. Manly JJ, Tang MX, Schupf N et al. Frequency and course of mild
cognitive impairment in a multiethnic community. Ann Neurol 2008; 63:
494–506.
5. Plassman BL, Langa KM, Fisher GG et al. Prevalence of cognitive
impairment without dementia in the United States. Ann Intern Med 2008;
148: 427–434.
6. Teschan PE. Electroencephalographic and other neurophysiological
abnormalities in uremia. Kidney Int Suppl 1975; 2: 210–216.
7. Arieff AI. Dialysis disequilibrium syndrome: current concepts on
pathogenesis and prevention. Kidney Int 1994; 45: 629–635.
8. Williams MA, Sklar AH, Burright RG et al. Temporal effects of dialysis on
cognitive functioning in patients with ESRD. Am J Kidney Dis 2004; 43:
705–711.
9. Murray AM, Pederson SL, Tupper DE et al. Acute variation in cognitive
function in hemodialysis patients: a cohort study with repeated
measures. Am J Kidney Dis 2007; 50: 270–278.
10. Kurella M, Chertow GM, Luan J et al. Cognitive impairment in chronic
kidney disease. J Am Geriatr Soc 2004; 52: 1863–1869.
11. Murray AM, Tupper DE, Knopman DS et al. Cognitive impairment in
hemodialysis patients is common. Neurology 2006; 67: 216–223.
12. Sehgal AR, Grey SF, DeOreo PB et al. Prevalence, recognition, and
implications of mental impairment among hemodialysis patients. Am J
Kidney Dis 1997; 30: 41–49.
13. Brady CB, Gaziano JM, Cxypoliski RA et al. Homocysteine lowering and
cognition in CKD: the Veterans Affairs homocysteine study. Am J Kidney
Dis 2009; 54: 440–449.
14. Cook WL, Jassal SV. Functional dependencies among the elderly on
hemodialysis. Kidney Int 2008; 73: 1289–1295.
15. Kurella Tamura M, Larive B, Unruh M et al. Prevalence and correlates of
cognitive impairment in the frequent hemodialysis network (FHN) trials.
Clin J Am Soc Nephrol 2010; 8: 1429–1438.
16. Leinau L, Murphy TE, Bradley E et al. Relationship between conditions
addressed by hemodialysis guidelines and non-ESRD-specific conditions
affecting quality of life. Clin J Am Soc Nephrol 2009; 4: 572–578.
17. Collins AJ, Kasiske B, Herzog C et al. Excerpts from the United States Renal
Data System 2006 Annual Data Report. Am J Kidney Dis 2007; 49: A6–A7,
S1-296.
18. Kurella M, Luan J, Yaffe K et al. Validation of the Kidney Disease
Quality of Life (KDQOL) cognitive function subscale. Kidney Int 2004; 66:
2361–2367.
19. Carrasco FR, Moreno A, Ridao N et al. Kidney transplantation
complications related to psychiatric or neurological disorders. Transplant
Proc 2009; 41: 2430–2432.
20. Ettenhofer ML, Hinkin CH, Castellon SA et al. Aging, neurocognition, and
medication adherence in HIV infection. Am J Geriatr Psychiatry 2009; 17:
281–290.
21. Sugarman J, McCrory DC, Hubal RC. Getting meaningful informed
consent from older adults: a structured literature review of empirical
research. J Am Geriatr Soc 1998; 46: 517–524.
22. Cohen LM, Ruthazer R, Moss AH et al. Predicting six-month mortality for
patients who are on maintenance hemodialysis. Clin J Am Soc Nephrol
2010; 5: 72–79.
23. Kurella M, Mapes DL, Port FK et al. Correlates and outcomes of dementia
among dialysis patients: the Dialysis Outcomes and Practice Patterns
Study. Nephrol Dial Transplant 2006; 21: 2543–2548.
24. Kurella Tamura M, Covinsky KE, Chertow GM et al. Functional status of
elderly adults before and after initiation of dialysis. N Engl J Med 2009;
361: 1539–1547.
25. Rakowski DA, Caillard S, Agodoa LY et al. Dementia as a predictor of
mortality in dialysis patients. Clin J Am Soc Nephrol 2006; 1: 1000–1005.
26. Kurella M, Chertow GM, Fried LF et al. Chronic kidney disease and
cognitive impairment in the elderly: the health, aging, and body
composition study. J Am Soc Nephrol 2005; 16: 2127–2133.
27. Seliger SL, Siscovick DS, Stehman-Breen CO et al. Moderate renal
impairment and risk of dementia among older adults: the Cardiovascular
Health Cognition Study. J Am Soc Nephrol 2004; 15: 1904–1911.
28. Khatri M, Nickolas T, Moon YP et al. CKD associates with cognitive decline.
J Am Soc Nephrol 2009; 20: 2427–2432.
29. Kurella M, Yaffe K, Shlipak MG et al. Chronic kidney disease and cognitive
impairment in menopausal women. Am J Kidney Dis 2005; 45: 66–76.
30. Kurella Tamura M, Wadley V, Yaffe K et al. Kidney function and cognitive
impairment in US adults: the Reasons for Geographic and Racial
Differences in Stroke (REGARDS) Study. Am J Kidney Dis 2008; 52:
227–234.
31. Ikram MA, Vernooij MW, Hofman A et al. Kidney function is related to
cerebral small vessel disease. Stroke 2008; 39: 55–61.
32. Nakatani T, Naganuma T, Uchida J et al. Silent cerebral infarction in
hemodialysis patients. Am J Nephrol 2003; 23: 86–90.
33. Seliger SL, Longstreth Jr WT, Katz R et al. Cystatin C and subclinical brain
infarction. J Am Soc Nephrol 2005; 16: 3721–3727.
34. Kobayashi S, Ikeda T, Moriya H et al. Asymptomatic cerebral lacunae in
patients with chronic kidney disease. Am J Kidney Dis 2004; 44: 35–41.
35. Naganuma T, Uchida J, Tsuchida K et al. Silent cerebral infarction predicts
vascular events in hemodialysis patients. Kidney Int 2005; 67: 2434–2439.
36. Uzu T, Kida Y, Shirahashi N et al. Cerebral microvascular disease predicts
renal failure in type 2 diabetes. J Am Soc Nephrol 2010; 21: 520–526.
37. Fukunishi I, Kitaoka T, Shirai T et al. Psychiatric disorders among patients
undergoing hemodialysis therapy. Nephron 2002; 91: 344–347.
38. Fotuhi M, Hachinski V, Whitehouse PJ. Changing perspectives regarding
late-life dementia. Nat Rev Neurol 2009; 5: 649–658.
39. Fazekas G, Fazekas F, Schmidt R et al. Brain MRI findings and cognitive
impairment in patients undergoing chronic hemodialysis treatment.
J Neurol Sci 1995; 134: 83–88.
40. Fazekas G, Fazekas F, Schmidt R et al. Pattern of cerebral blood flow and
cognition in patients undergoing chronic haemodialysis treatment. Nucl
Med Commun 1996; 17: 603–608.
41. Hsieh TJ, Chang JM, Chuang HY et al. End-stage renal disease: in vivo
diffusion-tensor imaging of silent white matter damage. Radiology 2009;
252: 518–525.
42. Barzilay JI, Fitzpatrick AL, Luchsinger J et al. Albuminuria and dementia in
the elderly: a community study. Am J Kidney Dis 2008; 52: 216–226.
43. Vupputuri S, Shoham DA, Hogan SL et al. Microalbuminuria, peripheral
artery disease, and cognitive function. Kidney Int 2008; 73: 341–346.
44. Weiner DE, Bartolomei K, Scott T et al. Albuminuria, cognitive
functioning, and white matter hyperintensities in homebound elders.
Am J Kidney Dis 2009; 3: 438–447.
45. Lin C, Wang ST, Wu CW et al. The association of a cystatin C gene
polymorphism with late-onset Alzheimer’s disease and vascular
dementia. Chin J Physiol 2003; 46: 111–115.
46. Sarnak MJ, Katz R, Fried LF et al. Cystatin C and aging success. Arch Intern
Med 2008; 168: 147–153.
47. Yaffe K, Lindquist K, Shlipak MG et al. Cystatin C as a marker of cognitive
function in elders: findings from the health ABC study. Ann Neurol 2008;
63: 798–802.
48. Rosano C, Naydeck B, Kuller LH et al. Coronary artery calcium: associations
with brain magnetic resonance imaging abnormalities and cognitive
status. J Am Geriatr Soc 2005; 53: 609–615.
49. Holsinger T, Deveau J, Boustani M et al. Does this patient have dementia?
JAMA 2007; 297: 2391–2404.
50. Tariq SH, Tumosa N, Chibnall JT et al. Comparison of the Saint Louis
University mental status examination and the mini-mental state
examination for detecting dementia and mild neurocognitive disorder –a
pilot study. Am J Geriatr Psychiatry 2006; 14: 900–910.
51. Nasreddine ZS, Phillips NA, Bedirian V et al. The Montreal Cognitive
Assessment, MoCA: a brief screening tool for mild cognitive impairment.
J Am Geriatr Soc 2005; 53: 695–699.
52. Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’. A practical
method for grading the cognitive state of patients for the clinician.
J Psychiatr Res 1975; 12: 189–198.
53. Tangalos EG, Smith GE, Ivnik RJ et al. The Mini-Mental State Examination
in general medical practice: clinical utility and acceptance. Mayo Clin Proc
1996; 71: 829–837.
54. Crum RM, Anthony JC, Bassett SS et al. Population-based norms for the
Mini-Mental State Examination by age and educational level. JAMA 1993;
269: 2386–2391.
55. Pereira AA, Weiner DE, Scott T et al. Subcortical cognitive impairment in
dialysis patients. Hemodial Int 2007; 11: 309–314.
56. Memantine (package insert). St Louis, MO, 2007.
57. Tacrine hydrochlorine (package insert). Atlanta, GA, 2008.
58. Donepezil hydrochloride (package insert). Sellersville, PA, 2008.
59. Rivastigmine tartrate (package insert). East Hanover, NJ, 2010.
60. Galantamine (package insert). Sellersville, PA, 2008.
61. Langa KM, Foster NL, Larson EB. Mixed dementia: emerging concepts and
therapeutic implications. JAMA 2004; 292: 2901–2908.
Kidney International (2011) 79, 14–22 21
M Kurella Tamura and K Yaffe: Dementia and cognitive impairment in ESRD min i rev iew
62. Schneider LS, Tariot PN, Dagerman KS et al. Effectiveness of atypical
antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med
2006; 355: 1525–1538.
63. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the
treatment of aggression and psychosis in Alzheimer’s disease. Cochrane
Database Syst Rev 2006; (1): CD003476.
64. Peters R, Beckett N, Forette F et al. Incident dementia and blood pressure
lowering in the Hypertension in the Very Elderly Trial cognitive function
assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet
Neurol 2008; 7: 683–689.
65. McGuinness B, Todd S, Passmore P et al. Blood pressure lowering in
patients without prior cerebrovascular disease for prevention of cognitive
impairment and dementia. Cochrane Database Syst Rev 2009; (4):
CD004034.
66. Lautenschlager NT, Cox KL, Flicker L et al. Effect of physical activity on
cognitive function in older adults at risk for Alzheimer disease: a
randomized trial. JAMA 2008; 300: 1027–1037.
67. Grimm G, Stockenhuber F, Schneeweiss B et al. Improvement of brain
function in hemodialysis patients treated with erythropoietin. Kidney Int
1990; 38: 480–486.
68. Marsh JT, Brown WS, Wolcott D et al. rHuEPO treatment improves brain and
cognitive function of anemic dialysis patients. Kidney Int 1991; 39: 155–163.
69. Pickett JL, Theberge DC, Brown WS et al. Normalizing hematocrit in
dialysis patients improves brain function. Am J Kidney Dis 1999; 33:
1122–1130.
70. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type
2 diabetes and chronic kidney disease. N Engl J Med 2009; 361:
2019–2032.
71. Jassal SV, Devins GM, Chan CT et al. Improvements in cognition in
patients converting from thrice weekly hemodialysis to nocturnal
hemodialysis: a longitudinal pilot study. Kidney Int 2006; 70:
956–962.
72. Griva K, Thompson D, Jayasena D et al. Cognitive functioning pre- to
post-kidney transplantation –a prospective study. Nephrol Dial Transplant
2006; 21: 3275–3282.
73. Gelb S, Shapiro RJ, Hill A et al. Cognitive outcome following
kidney transplantation. Nephrol Dial Transplant 2008; 23:
1032–1038.
74. Moss AH. Shared decision-making in dialysis: the new RPA/ASN guideline
on appropriate initiation and withdrawal of treatment. Am J Kidney Dis
2001; 37: 1081–1091.
75. Moss AH, Stocking CB, Sachs GA et al. Variation in the attitudes of dialysis
unit medical directors toward decisions to withhold and withdraw
dialysis. J Am Soc Nephrol 1993; 4: 229–234.
22 Kidney International (2011) 79, 14–22
min i rev iew M Kurella Tamura and K Yaffe: Dementia and cognitive impairment in ESRD
